Icon Wealth Advisors LLC Acquires 2,316 Shares of Stryker Co. (NYSE:SYK)

Icon Wealth Advisors LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 461.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,818 shares of the medical technology company’s stock after acquiring an additional 2,316 shares during the quarter. Icon Wealth Advisors LLC’s holdings in Stryker were worth $1,018,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its position in Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after purchasing an additional 58,673 shares during the period. OFI Invest Asset Management increased its position in shares of Stryker by 3,210.9% during the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after purchasing an additional 3,243 shares during the last quarter. Tidal Investments LLC raised its holdings in Stryker by 14.2% during the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company’s stock valued at $4,853,000 after buying an additional 1,681 shares during the period. Envestnet Asset Management Inc. boosted its stake in Stryker by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after buying an additional 16,504 shares during the period. Finally, Sivik Global Healthcare LLC increased its position in Stryker by 8.0% during the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 1.3 %

NYSE SYK opened at $384.88 on Friday. Stryker Co. has a one year low of $285.79 and a one year high of $398.20. The firm has a 50 day simple moving average of $366.20 and a 200-day simple moving average of $349.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $146.72 billion, a price-to-earnings ratio of 41.25, a PEG ratio of 2.94 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the prior year, the firm posted $2.46 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at $3,685,213.16. This represents a 42.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 over the last 90 days. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Barclays raised their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday. Canaccord Genuity Group upped their price objective on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC lifted their target price on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup upped their price target on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.